Features

The Programmable Pill

  • May 2001
  • By Alexandra Stikeman

Drugs of the near future will be microdevices that search out and destroy germs without the side effects of conventional therapies.

   

The patient leans back in his chair and closes his eyes, waiting to receive his first chemotherapy treatment for advanced colon cancer. His nurse locates the tiny catheter just beneath the skin of his chest and connects it to an IV tube. A clear fluid containing an anticancer drug travels down the tube, through the catheter and into the man's blood vessels. The drug travels throughout his body in search of the fast-dividing cells characteristic of cancer-but only a relatively small portion of the drug will reach those cells. Instead, much of it will end up attacking hair follicles, immune system cells and tissues where noncancerous cells are dividing quickly. The treatment lasts an hour as the patient sits there, apprehensive not only about his disease but about side effects. Will he lose his hair? Will he feel nauseous? A few hours later, nausea sets in. By the next treatment, the hair loss he feared has begun.

Now fast-forward 10 years or so. Gone are the catheter and the shotgun approach. In their place is a remarkable little particle, invisible to the naked eye, that contains far more intelligence than the entire current system of drug delivery. Taken orally, the particle passes undisturbed through the stomach and small intestine and into the colon, where it homes in directly on the tumor cells. There, it releases a powerful anticancer drug that destroys just the cancerous cells-with no side effects.

Sound far-fetched? Well, it isn't possible yet. But it could be quite soon, thanks to a new generation of "smart" delivery vehicles under development at a handful of universities and startup companies. These new methods offer the ability to precisely control the timing of a drug's release. What's more, they aim for laserlike targeting of just the right tissues and cells. And a little farther in the future lies the capacity to operate autonomously, gathering feedback from the body and adjusting treatment accordingly. The pioneers in this young field believe they will bring the first of these new weapons against disease into clinical trials as soon as five years from now, freeing patients from the pain and side effects of pills and injections, and also opening the door to whole new classes of treatments that aren't possible with today's delivery systems.

Gathering Speed

 

To read the entire article you must log in:

Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.

Username or REGISTER
Password  
   
 
Advertisement

MAGAZINE

Can We Build Tomorrow's Breakthroughs?

Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.

Videos

Meet 2011 TR35 Winner June Andronick

More

Advertisement

Technology Review Lists

TR50

Our list of the 50 most innovative companies, including the following:

Square

Geron

Groupon

Twitter

More

Advertisement

Facebook

Advertisement